ArticleLife (Basel, Switzerland)2025
A Fusion Deep Learning Model for Predicting Adverse Drug Reactions Based on Multiple Drug Characteristics.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early prediction and risk assessment of adverse drug combinations using ensemble learning.Scientific reports · 2026Article
- Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI)-assisted prediction of adverse drug reactions (ADRs) has significant potential for improving drug safety and reducing financial costs. Early studies often relied on limited dimensions such as the molecular structure of drugs or interactions with biomolecules. In contrast, integrating these characteristics provides valuable insights into ADR predictions from multiple perspectives, enhancing the comprehensiveness and accuracy of the prediction models. In addition, previous studies have focused on whether a specific adverse drug reaction occurs with a particular drug, ignoring the fact that multiple adverse drug reactions may occur concurrently with a single drug. To address these, we developed a predictor that identifies ADRs early in drug discovery, using a deep learning model designed to fuse multiple drug characteristics. Our approach employed four modules to extract one- and two-dimensional sequence structure information of drug molecules, drug-protein interaction data, and drug similarity. A fusion model integrated these characteristics to predict the precise probability of ADRs. The receiver operating characteristic-area under curve (ROC-AUC), area under precision-recall curve (AUPR), and F1 scores on the benchmark dataset are 0.7002, 0.6619, and 0.6330, respectively. The AUPR is significantly improved compared to the conventional multi-label classifier (from 64.02% to 66.19%). In addition, we compared the results with the state-of-the-art methods on LIU's dataset and the AUPR increased from 34.65% to 68.82%, which shows that our model outperforms them in terms of accuracy and robustness. Ablation experiments further validated the effectiveness of the individual modules. This model accurately predicted the probability of various ADR classes by integrating comprehensive information, thereby offering significant value in enhancing monitoring measures for new drug development and clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.